ALX Oncology Q3 net loss per share narrows
ALXO•ALX Oncology’s third-quarter net loss was $21.83 million, while loss per share narrowed to $0.15, mainly because of a higher average share count. The company ended the quarter with $147.2 million in cash and expects it to fund operations through the first half of 2028.
1. Quarterly results
ALX Oncology reported a third-quarter net loss of $21.83 million and operating expenses of $22.95 million, both largely unchanged from the prior year. Loss per basic share narrowed to $0.15, mainly due to a higher average number of shares outstanding.
2. Cash and trial costs
The company ended the quarter with $147.2 million in cash and expects to fund operations through the first half of 2028. Research and development expenses reflected increased site activations and patient enrollment in evorpacept and ALX2004 trials, partly offset by the absence of a $2.5 million development milestone payment made in the prior period.




